Total Payments
$5,130
2024 Payments
$408.13
Companies
8
Transactions
179
Medicare Patients
2,124
Medicare Billing
$235,906
Payment Breakdown by Category
Food & Beverage$4,105 (80.0%)
Consulting$1,000 (19.5%)
Education$25.00 (0.5%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $4,105 | 177 | 80.0% |
| Consulting Fee | $1,000 | 1 | 19.5% |
| Education | $25.00 | 1 | 0.5% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Optinose US, Inc. | $3,195 | 91 | $0 (2024) |
| PFIZER INC. | $751.23 | 22 | $0 (2024) |
| Genentech USA, Inc. | $639.74 | 40 | $0 (2022) |
| Paratek Pharmaceuticals, Inc. | $301.94 | 11 | $0 (2024) |
| Nabriva Therapeutics, plc | $168.93 | 11 | $0 (2022) |
| Teva Pharmaceuticals USA, Inc. | $41.94 | 2 | $0 (2017) |
| Novartis Pharmaceuticals Corporation | $16.97 | 1 | $0 (2018) |
| Mission Pharmacal Company | $14.41 | 1 | $0 (2019) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $408.13 | 6 | Optinose US, Inc. ($155.87) |
| 2023 | $560.26 | 19 | Optinose US, Inc. ($300.32) |
| 2022 | $2,033 | 46 | OptiNose US, Inc. ($1,734) |
| 2021 | $869.13 | 47 | Optinose US, Inc. ($589.27) |
| 2020 | $652.18 | 30 | OptiNose US, Inc. ($415.54) |
| 2019 | $326.57 | 16 | PFIZER INC. ($166.36) |
| 2018 | $226.09 | 12 | PFIZER INC. ($191.49) |
| 2017 | $55.27 | 3 | Teva Pharmaceuticals USA, Inc. ($41.94) |
All Payment Transactions
179 individual payment records from CMS Open Payments — Page 1 of 8
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 10/17/2024 | PFIZER INC. | ABRYSVO (Biological) | Food and Beverage | In-kind items and services | $119.92 | General |
| Category: VACCINES | ||||||
| 10/02/2024 | Paratek Pharmaceuticals, Inc. | NUZYRA (Drug) | Food and Beverage | In-kind items and services | $116.06 | General |
| Category: ANTIBIOTIC | ||||||
| 06/12/2024 | Optinose US, Inc. | Xhance (Drug) | Food and Beverage | In-kind items and services | $123.84 | General |
| Category: Otolaryngology (Ear, Nose, Throat) | ||||||
| 06/10/2024 | Optinose US, Inc. | Xhance (Drug) | Food and Beverage | In-kind items and services | $16.25 | General |
| Category: Otolaryngology (Ear, Nose, Throat) | ||||||
| 04/19/2024 | PFIZER INC. | PAXLOVID (Drug) | Food and Beverage | In-kind items and services | $16.28 | General |
| Category: INFECTIOUS DISEASES | ||||||
| 02/01/2024 | Optinose US, Inc. | Xhance (Drug) | Food and Beverage | In-kind items and services | $15.78 | General |
| Category: Otolaryngology (Ear, Nose, Throat) | ||||||
| 11/16/2023 | PFIZER INC. | ABRYSVO (Biological) | Food and Beverage | In-kind items and services | $117.38 | General |
| Category: VACCINES | ||||||
| 11/03/2023 | Optinose US, Inc. | Xhance (Drug) | Food and Beverage | In-kind items and services | $12.29 | General |
| Category: Otolaryngology (Ear, Nose, Throat) | ||||||
| 09/21/2023 | Optinose US, Inc. | Xhance (Drug) | Food and Beverage | In-kind items and services | $20.90 | General |
| Category: Otolaryngology (Ear, Nose, Throat) | ||||||
| 08/31/2023 | Optinose US, Inc. | Xhance (Drug) | Food and Beverage | In-kind items and services | $21.87 | General |
| Category: Otolaryngology (Ear, Nose, Throat) | ||||||
| 08/04/2023 | PFIZER INC. | PAXLOVID (Drug) | Food and Beverage | In-kind items and services | $126.47 | General |
| Category: INFECTIOUS DISEASES | ||||||
| 07/13/2023 | Optinose US, Inc. | Xhance (Drug) | Food and Beverage | In-kind items and services | $20.57 | General |
| Category: Otolaryngology (Ear, Nose, Throat) | ||||||
| 06/15/2023 | Optinose US, Inc. | Xhance (Drug) | Food and Beverage | In-kind items and services | $21.03 | General |
| Category: Otolaryngology (Ear, Nose, Throat) | ||||||
| 05/19/2023 | Optinose US, Inc. | Xhance (Drug) | Food and Beverage | In-kind items and services | $20.79 | General |
| Category: Otolaryngology (Ear, Nose, Throat) | ||||||
| 04/28/2023 | Optinose US, Inc. | Xhance (Drug) | Food and Beverage | In-kind items and services | $20.11 | General |
| Category: Otolaryngology (Ear, Nose, Throat) | ||||||
| 04/28/2023 | Optinose US, Inc. | Xhance (Drug) | Food and Beverage | In-kind items and services | $0.65 | General |
| Category: Otolaryngology (Ear, Nose, Throat) | ||||||
| 04/14/2023 | Optinose US, Inc. | Xhance (Drug) | Food and Beverage | In-kind items and services | $18.85 | General |
| Category: Otolaryngology (Ear, Nose, Throat) | ||||||
| 03/30/2023 | Optinose US, Inc. | Xhance (Drug) | Food and Beverage | In-kind items and services | $17.01 | General |
| Category: Otolaryngology (Ear, Nose, Throat) | ||||||
| 03/17/2023 | Optinose US, Inc. | Xhance (Drug) | Food and Beverage | In-kind items and services | $24.25 | General |
| Category: Otolaryngology (Ear, Nose, Throat) | ||||||
| 02/24/2023 | Optinose US, Inc. | Xhance (Drug) | Food and Beverage | In-kind items and services | $24.63 | General |
| Category: Otolaryngology (Ear, Nose, Throat) | ||||||
| 02/15/2023 | Optinose US, Inc. | Xhance (Drug) | Food and Beverage | In-kind items and services | $18.42 | General |
| Category: Otolaryngology (Ear, Nose, Throat) | ||||||
| 02/02/2023 | Optinose US, Inc. | Xhance (Drug) | Food and Beverage | In-kind items and services | $13.78 | General |
| Category: Otolaryngology (Ear, Nose, Throat) | ||||||
| 01/24/2023 | Paratek Pharmaceuticals, Inc. | NUZYRA (Drug) | Food and Beverage | In-kind items and services | $16.09 | General |
| Category: ANTIBIOTIC | ||||||
| 01/20/2023 | Optinose US, Inc. | Xhance (Drug) | Food and Beverage | In-kind items and services | $23.97 | General |
| Category: Otolaryngology (Ear, Nose, Throat) | ||||||
| 01/18/2023 | Optinose US, Inc. | Xhance (Drug) | Food and Beverage | In-kind items and services | $21.20 | General |
| Category: Otolaryngology (Ear, Nose, Throat) | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 1 | 11 | 11 | $2,200 | $949.02 |
| 2022 | 7 | 761 | 859 | $151,119 | $89,081 |
| 2021 | 8 | 928 | 1,001 | $175,772 | $106,309 |
| 2020 | 8 | 424 | 447 | $82,574 | $39,568 |
Total Patients
2,124
Total Services
2,318
Medicare Billing
$235,906
Procedure Codes
24
All Medicare Procedures & Services
24 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 11 | 11 | $2,200 | $949.02 | 43.1% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 240 | 312 | $58,644 | $31,842 | 54.3% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2022 | 191 | 191 | $37,168 | $24,534 | 66.0% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 119 | 130 | $25,217 | $16,339 | 64.8% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 66 | 66 | $19,210 | $11,096 | 57.8% |
| 87811 | Detection test by immunoassay with direct visual observation for severe acute respiratory syndrome coronavirus 2 (covid-19) | Office | 2022 | 95 | 107 | $8,855 | $4,394 | 49.6% |
| 71046 | X-ray of chest, 2 views | Office | 2022 | 27 | 27 | $1,905 | $819.12 | 43.0% |
| 81003 | Automated urinalysis test | Office | 2022 | 23 | 26 | $120.12 | $57.52 | 47.9% |
| 99203 | New patient outpatient visit, total time 30-44 minutes | Office | 2021 | 344 | 344 | $66,595 | $44,495 | 66.8% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 243 | 293 | $54,155 | $30,144 | 55.7% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 96 | 107 | $20,220 | $13,357 | 66.1% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Office | 2021 | 74 | 74 | $21,538 | $11,986 | 55.7% |
| 87811 | Sars-cov-2 covid19 w/optic | Office | 2021 | 96 | 107 | $8,855 | $4,428 | 50.0% |
| 87426 | Elisa detection of severe acute respiratory syndrome coronavirus 2 (covid-19) antigen | Office | 2021 | 31 | 31 | $2,325 | $1,095 | 47.1% |
| 71046 | X-ray of chest, 2 views | Office | 2021 | 27 | 27 | $2,000 | $763.37 | 38.2% |
| 81003 | Automated urinalysis test | Office | 2021 | 17 | 18 | $83.16 | $40.50 | 48.7% |
| 99204 | New patient office or other outpatient visit, typically 45 minutes | Office | 2020 | 83 | 83 | $24,152 | $11,129 | 46.1% |
| 99203 | New patient office or other outpatient visit, typically 30 minutes | Office | 2020 | 84 | 84 | $16,262 | $10,318 | 63.4% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 112 | 128 | $24,256 | $10,123 | 41.7% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Office | 2020 | 68 | 74 | $13,183 | $6,074 | 46.1% |
| 87635 | Sars-cov-2 covid-19 amp prb | Office | 2020 | 14 | 14 | $1,400 | $718.34 | 51.3% |
| 71046 | X-ray of chest, 2 views | Office | 2020 | 28 | 28 | $2,100 | $628.64 | 29.9% |
| 87426 | Coronavirus ag ia | Office | 2020 | 15 | 15 | $1,125 | $529.95 | 47.1% |
| 81003 | Automated urinalysis test | Office | 2020 | 20 | 21 | $97.02 | $47.00 | 48.4% |
About Dr. Larry Moy, M.D
Dr. Larry Moy, M.D is a Occupational Medicine healthcare provider based in Stamford, Connecticut. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 03/23/2007. The National Provider Identifier (NPI) number assigned to this provider is 1801913884.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Larry Moy, M.D has received a total of $5,130 in payments from pharmaceutical and medical device companies, with $408.13 received in 2024. These payments were reported across 179 transactions from 8 companies. The most common payment nature is "Food and Beverage" ($4,105).
As a Medicare-enrolled provider, Moy has provided services to 2,124 Medicare beneficiaries, totaling 2,318 services with total Medicare billing of $235,906. Data is available for 4 years (2020–2023), covering 24 distinct procedure/service records.
Ad
Practice Information
- Specialty Occupational Medicine
- Location Stamford, CT
- Active Since 03/23/2007
- Last Updated 07/08/2007
- Taxonomy Code 2083X0100X
- Entity Type Individual
- NPI Number 1801913884
Products in Payments
- Xhance (Drug) $3,195
- Xofluza (Drug) $639.74
- NUZYRA (Drug) $301.94
- ABRYSVO (Biological) $237.30
- EUCRISA (Drug) $232.85
- Xenleta (Drug) $168.93
- PAXLOVID (Drug) $142.75
- COLOGUARD (Device) $125.00
- QVAR (Drug) $25.00
- CIPRODEX (Drug) $16.97
- AMRIX (Drug) $16.94
- Uribel (Drug) $14.41
- VIAGRA (Drug) $13.33
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.